FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 467 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR What to Know About Biomarker Testing for Lung Cancer: An Expert... June 9, 2022 Men’s skin cancer rates increase by 50% over decade June 24, 2021 A new year of expanding research horizons January 21, 2022 A New Study Suggests Screen Time Might Not Be The Worst... November 14, 2019 Load more HOT NEWS Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See... Though the Pandemic Has Slowed, Many Are Still Struggling to Put... Selumetinib Approved by FDA to Treat Children with NF1 “My First Thought Was My Children:” Young Mom Diagnosed With Triple-Negative...
